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Abstract
Introduction Almost all pediatric lymphomas are malignant,
high-grade tumors. The combined incidence of Hodgkin’s
disease (HD) and non-Hodgkin lymphoma (NHL) reaches
10 to 12 new cases a year per million children under the age
of 16 years, representing about 10% of all pediatric cancers.
HD makes up to 40% and NHL 60% of pediatric lympho-
mas. During the last 20 years, cure rates raised dramatically
so that currently over 90% of children and adolescents with
HD and about 80% of those with NHL can be cured. As cure
can be achieved in a large majority of patients, long-term
effects and quality of life of the survivors are nowadays the
principal challenges to pediatric oncologists.
Discussion Like survivors from acute lymphoblastic leuke-
mia, young adults cured from NHL may present with
neurocognitive deficits, especially if treated at a young age
and with cranial irradiation. Intrathecal or high-dose
intravenous chemotherapy with methotrexate may induce
the same problems, although in a lesser extent and severity.
Large enough prospective cohort studies like the CCSS in
the USA were able to show an increased risk of second
malignant neoplasms, especially brain tumors in patients
formerly treated with cranial irradiation. Reduced fertility
can follow exposure to cyclophosphamide, especially in the
male. Cardiac function must be serially evaluated over the
long to very long-term because of potential cardiomyopathy
after high anthracycline doses and/or mediastinal irradiation.
Survivors from HD are at high risk of late complications.
Radiation therapy to the neck and mediastinum (mantle
field) induces a 50% risk of developing hypothyroidism
and a 20% risk of developing thyroid nodules at 20 years.
The risk of thyroid cancer is 18 times higher the expected
rate for the general population. Secondary aggressive breast
cancer shows a cumulative risk of 30% at 30 years after
radiotherapy. Other structures affected by mediastinal irra-
diation are the heart (pericardial, myocardial and endocardial
structures), the great arteries (fibrosis, stenosis, aneurysms)
and the central portion of the lungs (diffusion troubles,
restrictive pneumopathy). Cardiac toxicity can be enhanced
by the concomitant therapy with adriamycin and lung
toxicity by bleomycin. Radiotherapy to the paraaortic and
iliacal lymph nodes can affect gonadal function both in males
and females; concomitant chemotherapy with alkylating
agents like cyclophosphamide and especially procarbazine
have a synergistic action and can lead to premature
menopause as well as infertility.
Although the vast majority of survivors from pediatric
lymphomas fare well, a minority present with extreme
symptoms of depression and psychosomatic distress;
female sex, low socio-economic status and treatment with
intensive chemotherapy are important risk factors for a poor
psychosocial outcome.
Conclusion It is therefore crucial, but not always easy, to
inform patients and families about potential late effects and
organize follow-up after the pediatric age. Awell functioning
network of pediatric oncologists, GP’s, adult oncologists and
other specialists of adult medicine must be developed in
order to prevent, early detect and treat expected long-term
toxicities.
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Late effects
Introduction
During the last 40 years, dramatic improvements have
been achieved in the treatment of pediatric lymphomas.
In Hodgkin’s disease, over 90% of patients can be cured;
in non-Hodgkin’s lymphoma (NHL) about 80%. With
improved survival, concerns and issues related to long-
term toxicities and quality of life of the survivors become
a crucial point of interest.
In this paper, we will review selected late effects,
focusing on those with the major impact on late mortality
or morbidity and on health-related quality of life. These
include second malignancies, cardiotoxicity, endocrine and
neuropsychological deficits.
Two main challenges arise when studying late compli-
cations of childhood cancer. The first is the fact that
treatments continuously evolve over time and the second
is the occurrence of very late complications of treatments
applied three or more decades ago. As treatment- and
patient-related factors impact the risk of late adverse
outcomes, it is essential to clearly delineate those survivors
at high risk of specific complications for the rational design
of the medical follow-up and the implementation of
preventive and interventional measures.
Second malignancies
Survivors of pediatric and adolescent Hodgkin’s disease
clearly represent a subgroup of patients at high- to very
high risk of secondary malignancies. This is particularly
true for those children treated many decades ago with
predominantly radiation-based therapies: they show an
approximately tenfold increased risk of developing a
second cancer [25]. MOPP or COPP (mechlorethamine,
cyclophosphamide, vincristine, procarbazine, prednisone)
based regimens significantly increase the risk for secondary
leukemias [38, 15]. Classically, these alkylating-agents-
related leukemias arise early (2 to 10 years, mean 7 years)
after Hodgkin’s treatment, show typical cytogenetical
abnormalities (e.g. monosomy 5 or 7) and often develop
as acute myeloid leukemia (AML) on the background of a
myelodysplastic syndrome [9]. Interestingly, patient-related
factors identified as polymorphisms in specific drug-
metabolizing enzymes modulate the risk of developing
secondary leukemias. Patients with the NQO1 (NAD(P)H:
quinine oxydoreductase) polymorphism are statistically at
higher risk of developing therapy-related AML and
myelodysplasia [2, 24]. Individuals with the CYP3A4-W
genotype accumulate intermediate reactive metabolites that
may damage DNA [10].
Breast cancer is the most frequent secondary solid tumor
reported in Hodgkin’s disease female survivors treated with
mantle field radiation but has also been described in males.
In contrast to secondary leukemias, the incidence of solid
tumors doesn’t plateau after 10 years but shows a con-
tinuous increase over time [22, 25]. In a recent paper from
the Childhood Cancer Survivors Study (CCSS, the world’s
largest cohort of pediatric cancer survivors with currently
more than 25,000 people in follow-up), Bathia et al. [1]
reported on a cumulative incidence of developing a sec-
ondary breast carcinoma approaching 20% at 45 years of
age. Typically, these cancers are located in the internal
quadrants of the breast, frequently (in about 40% of cases)
bilateral and biologically more aggressive than primary
breast cancer. The second most frequent radiation-induced
cancer is thyroid carcinoma, which again occurs more fre-
quently in women and at about a 36-fold increased rate
compared to the general population. Iterative screening by
cervical ultrasound is important in order to detect tumors at
an early stage and be curative with surgery only.
With the growing and ageing population of survivors,
excess risks for other solid tumors like lung, gastro-
intestinal carcinomas but also bone and brain tumors have
already been disclosed in the early cohorts [20].
Second malignancies are significantly more uncommon
in survivors from NHL (Table 1). Like in acute lympho-
blastic leukemia (ALL), most of them are brain tumors and
thyroid carcinomas in patients formerly treated with CNS
radiation. Here again, besides these treatment-related
factors, patient-related ones could be highlighted. An earlier
age at diagnosis and specific genetic polymorphisms, like
thiopurine S-methyltransferase (TPMT), were predictive
of the risk of secondary CNS tumors in ALL survivors
[30]. Secondary AML has been described in patients with
ALL and NHL formerly treated with epipodophyllotoxins
(topoisomerase-II inhibitors). This kind of secondary AML
is characterized by an earlier onset (3 to 5 years from NHL
therapy) as alkylating-agents-associated AML, by the
presence of 11q23 rearrangements (mutations in the MLL
gene) and is more dependent on the administration’s sched-
ule than on the cumulative dose [29, 37] (Tables 2 and 3).
Cardiotoxicity
Survivors from pediatric Hodgkin’s disease, especially
those treated in early eras, are at increased risk for late
cardiac complications and even cardiac death. Mantle field
irradiation at doses around or above 40 Gy can induce
damages to the three main cardiac components: pericardium
with chronic constrictive pericarditis as a late consequence;
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myocardial fibrosis and endocardial thickening and valvular
stenoses or insufficiencies. In a small unpublished series of
76 Swiss Hodgkin’s survivors treated between 1970 and
1985 and evaluated in the year 2000, we found an 18%
prevalence of late, asymptomatic cardiac injuries; endo-
cardial and valvular damage represented one half of this
burden, myocardial disease (dilated cardiomyopathy) one
third and pericardial damage the rest.
Furthermore, post-actinic changes affecting the great
vessels as well as the coronary arteries have been described
in survivors from early cohorts having received high doses
of mantle field radiation without optimal cardiac shielding
[7]. Premature atherosclerosis and acute myocardial
infarction are relevant complications of mediastinal irra-
diation. In the Stanford series [12], there is a 45-fold
excess mortality risk from acute myocardial infarction in
patients treated with more than 30 Gy of mediastinal
irradiation before the age of 20 years. With lower volumes
and doses of radiation combined with optimal cardiac
shielding, the risk of radiation-induced cardiac injury
can be dramatically reduced. In a very recent study from
Toronto [5] reporting on children and adolescents treated
in the 90s with MOPP/ABV and low-dose (15 Gy)
radiation, late cardiac complications were found in only
one (2.5%) of 43 survivors assessed with echocardio-
graphy 5 years after therapy.
Anthracycline-induced cardiomyopathy is a well docu-
mented late to very late effect in adult survivors from
both pediatric Hodgkin’s and non-Hodgkin’s lymphomas.
In Hodgkin’s disease, drug-induced toxicity often adds to
the radiation-induced toxicity discussed above; in NHL
patients, daunorubicin or doxorubicin alone can induce
myocardial damage in a dose-dependent way. A cumulative
anthracycline dose greater than 300 mg/m2 is associated
with an 11-fold increased risk of clinically relevant heart
failure, the risk increasing with the length of follow-up and
approaching 5% at 15 years after exposure [17]. When
looking at subclinical myocardial damage, studying left
ventricular morphology and function, numbers vary con-
siderably from one to the other study (from 0 to 57%)
mainly because of methodological differences: definition of
outcomes, heterogeneity of the patient populations studied,
etc. [18]. This makes an accurate evaluation of the poten-
tial long-term cardiac outcomes in anthracycline-exposed
patients very difficult, especially if considering also sub-
clinical findings; it is probably correct to state that there
may be no safe anthracycline dose to completely avoid late
cardiotoxicity.
Table 1 Occurrence of second malignancies among 5-year survivors of
childhood leukemia and lymphoma (adapted from Neglia et al. [25])
Diagnosis Observed/expected ratio
(95% confidence interval)
Cumulative
incidence at
20 years
Absolute
excess of
riska
Leukemia 5.66 (4.37–7.22) 2.1% 1.2
Hodgkin’s 9.70 (8.05–11.59) 7.6% 5.13
NHL 3.21 (1.76–5.39) 1.9% 0.89
a Risk is expressed at number of malignancies per 1,000 person-years
of follow-up
Table 2 Common late effects
after treatment for Hodgkin’s
disease in childhood (adapted
from Robison and Bathia [32])
AML Acute myeloid leukemia,
CHF congestive heart failure,
CNS central nervous system,
PTSD post-traumatic stress
disorder, Tx therapy, XRT
radiation therapy
Adverse outcome Treatment associated
with an increased risk
Factors associates with highest risk
Hypothyroidism XRT to the thyroid Increasing dose, females
Hypogonadism Alkylating agents,
pelvic XRT
Males, pubertal age at Tx in girls, higher
dose of alkylators
Breast cancer XRT to the chest Increasing dose, females
Myelodysplastic
syndrome/AML
Alkylating agents,
topoisomerase-II
inhibitors
Increasing dose of alkylators, older
age at Tx
Thyroid cancer XRT to the thyroid Increasing dose, females, younger age
at XRT
Skin cancer XRT Orthovoltage XRT; higher dose to the skin,
additional excessive exposure to sun,
tanning baths
Cardiomyopathy/CHF Anthracyclines High cumulative dose, females younger
than 5 years at Tx
Pulmonary fibrosis Bleomycin, XRT to the
chest, carmustine
Younger age at Tx, bleomycin
dose >400 U/m2
Myocardial infarction XRT to the chest Underlying risk factors (smoking,
hypertension, hyperlipidemia, obesity, etc.)
Psychosocial outcomes
(depression, anxiety, PTSD)
Females
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Endocrine sequelae
Radiation therapy to the neck (upper part of the mantle
field) is a well known risk factor for subsequent thyroid
disease. In survivors from Hodgkin’s disease and in a
markedly lesser extent from NHL, hypothyroidism, hyper-
thyroidism and benignant or malignant thyroid nodules
have been described. In a recent study from the CCSS [36],
about 34% of 1,791 5-year Hodgkin’s survivors had at least
one thyroid abnormality, hypothyroidism clearly being the
most frequent. In our own unpublished series (see above),
we found an overall prevalence of hypothyroidism reaching
43%, with a clear-cut dose–effect relationship: the preva-
lence was 51% in patients treated with 35–45 Gy compared
to 27% in patients treated with 15–25 Gy (p<0.05 in the
Chi2 test).
Growth hormone deficiency with poor linear growth
and reduced final height is a common complication of CNS
irradiation at doses above 15 to 18 Gy, typically in the dose
range used for prophylactic CNS treatment in acute
lymphoblastic leukemia and some, especially T-cell, NHL’s.
In chemotherapy-only treated patients with ALL or NHL,
the prevalence of short stature is very low, although there
are some conflicting results in the literature regarding the
impact of chemotherapy on final height [16, 35].
Cranial irradiation has also been recently related to an
increased prevalence of adult overweight (BMI 25–30) and
obesity (BMI >30), especially in female long-term survi-
vors of ALL followed in the CCSS [27]. Besides gender,
age at diagnosis of ALL was significantly correlated to the
risk of overweight/obesity, girls diagnosed under the age
of 4 years and treated with >20 Gy of cranial irradiation
showing an almost fourfold increase risk of obesity com-
pared to adult siblings of cancer survivors.
Both pelvic irradiation (infra-diaphragmatic inverted-Y
field) and alkylating agents like mechlorethamine, cyclo-
phosphamide and procarbazine (in MOPP and COPP
regimens) are highly gonadotoxic and primary gonadal
failure has been described both in male and female sur-
vivors from Hodgkin’s disease [8]. Pelvic radiation is
extremely deleterious to the germinal epithelium of the
testes and ovaries, leading to impaired fertility or sterility,
even after very low exposures (4 to 6 Gy) [34]. In males,
Leydig cell function is rarely affected with usually normal
pubertal development, testicular volume and sexual func-
tion. On the other hand, sterility is a big issue in male
survivors. Oligospermia may already exist at the time of
diagnosis in 30 to 40% of patients [4] but, despite of this,
sperm cryopreservation should always be considered before
initiating therapy in pubertal boys. Six to eight MOPP or
COPP cycles will lead to azoospermia in 80 to 90% of
survivors [21]. However, late (10 to 15 years later) recovery
of fertility has also been reported [6, 28], so that caution is
always required when discussing this prognosis with the
patients. Anthracycline (ABVD) or epipodophyllotoxin-
based (OEPA) regimens are distinctly less gonadotoxic
but also possibly less effective. In women, the deleterious
effects of pelvic irradiation can be prevented by the surgical
transfer of the ovaries to the midline (oophoropexy) [19].
Effects on the ovaries are very dependent on the age of the
Table 3 Common late effects
after treatment for NHL in
childhood (adapted from
Robison and Bathia [32])
AML Acute myeloid leukemia,
CHF congestive heart failure,
CNS central nervous system,
PTSD post-traumatic stress
disorder, Tx therapy, XRT
radiation therapy
Adverse outcome Treatment associated with an
increased risk
Factors associates with highest risk
Neurocognitive deficits Cranial XRT Females, younger age at Tx, increasing
XRT dose
Hypothyroidism XRT to the thyroid Increasing dose, females
Hypogonadism Alkylating agents;
craniospinal, pelvic or
gonadal XRT
Males, pubertal age at Tx in girls, higher
dose of alkylators
Osteopenia, osteoporosis Steroids, Methotrexate; cranial,
pelvic or gonadal XRT,
Associated hypothyroidism, hypogonadism
or GH-deficiency
Avascular necrosis
of bone
Steroids, high-dose XRT
on bone
Dexamethasone, adolescents, males
Secondary CNS tumor Cranial XRT Increasing XRT dose, younger age at Tx.
Myelodysplastic
syndrome, Secondary
AML
Alkylating agents,
topoisomerase-II inhibitors
Increasing dose of alkylators, older age
at Tx
Skin cancer XRT Orthovoltage XRT; higher dose to the skin,
additional excessive exposure to sun,
tanning baths
Cardiomyopathy/CHF Anthracyclines High cumulative dose, females younger
than 5 years at Tx
Dental abnormalities Cranial XRT Younger age at Tx
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woman at the time of therapy, with younger girls having the
higher probability of maintaining regular menses after
treatment [28]. Normal pregnancies can occur after oophor-
opexy and pelvic irradiation without increased risk of fetal
wastage or spontaneous abortion [14]. No increase in birth
defects could be observed in offspring of survivors when
compared with those of sibling controls. Treatment for girls
and teens with Hodgkin’s disease may carry a considerable
risk of endocrine ovarian failure, i.e. premature menopause.
As expected, females treated with alkylating agents and
inverted-Y irradiation have a 27-fold increased probability
of premature menopause: 42% of these women had reached
menopause at the age of 31 years compared to 5% in the
controls [3].
NHL survivors, like their ALL counterparts, are at low-
risk of infertility and delayed or impaired puberty,
especially if treated with modern conventional therapy.
The figure is clearly different in the subgroup of children
having needed an allogeneic bone marrow transplant, where
alkylating-based conditioning regimens and/or total body
irradiation show the same deleterious effects as in Hodgkin’s
disease [33].
Neuropsychological effects
Because of the lack of CNS damaging agents (neither in the
radiation nor in the chemotherapy) in the treatment of
Hodgkin’s disease, survivors don’t present with relevant
neurocognitive deficits when compared to normal sibling
controls. However, a recent analysis from the CCSS [41],
noted that NHL but also Hodgkin’s survivors were sig-
nificantly more likely to report depression or somatic dis-
tress than sibling controls. Furthermore, there is a recently
growing interest in the prevalence of sleep disturbances and
chronic fatigue syndrome in Hodgkin’s survivors [11]
which might contribute to depression in those patients.
Neuropsychological or neurocognitive sequelae are
among the most intensively studied topics in long-term
survivors of childhood ALL. Because of the mentioned
biological and therapeutical similarities between ALL and
NHL, most authors analyze these patients as a single group.
Main risk factors described in earlier studies were cranial
irradiation, young age at treatment and, although somewhat
more controversial, female sex [26, 13]. These outcome
studies have been directly responsible for the dramatic
reduction or even discarding of cranial irradiation for
most of these patients, especially those from the youngest
age groups. Unfortunately, late cognitive deficits, mainly
attention/concentration troubles, impaired auditive and visual
short-term memory and reduced speed of processing leading
to poor academic achievement have also been observed after
chemotherapy-only regimens in ALL and NHL [23]. In the
Swiss Late Effects Study [39], neuropsychological outcomes
of 35 CNS-irradiated and 106 non-irradiated (chemotherapy-
only) patients were compared using the full version of the
WISC-R® or WAIS-R® test. Statistically significant lower
scores in global and verbal IQ’s were found in formerly
irradiated children. Looking at the single items of the
Wechsler test, significantly lower scores were also found in
arithmetics, short-term verbal memory, speed of processing
and visuo-motor coordination, always in the group of
irradiated children. Globally, only 18% of the 141 survivors
presented with learning disabilities and 94% followed a
normal schooling. Looking at the chemotherapy-only sub-
group in more details and comparing it with survivors from
pediatric non-CNS solid tumors, we found that the global
intellectual performance as well as the proportion of patients
with learning disabilities (gIQ between 70 and 85) was the
same in both groups. Children younger than 6 years at
diagnosis and girls had significantly lower IQ scores than
older children and boys respectively [40]. Summarizing the
findings from both our studies and others, it can be said that
skipping cranial radiotherapy and replacing it with more
intensive systemic and intrathecal chemotherapy is feasible
in most ALL/NHL patients, oncologically as efficient as
prophylactic cranial irradiation and leads to a significant
reduction of the burden of late neuropsychological deficits.
Outlook
It is crucial to keep in mind that the late effects we observe
today are the consequence of Hodgkin’s and non-Hodgkin’s
lymphoma treatment strategies applied 20 to 30 years ago.
Knowledge gained on the prevalence of late to very late
toxicities led to the design of newer treatment strategies,
able to maintain excellent survival while reducing long-
term mortality and morbidity. An example of such an
improvement can be found in the aforementioned publica-
tion from the Toronto group in Hodgkin’s disease [5]: in
spite of an impressive reduction in chemo- and radiotherapy
intensity, no negative impact was found on 10-year EFS or
OS (88 vs 94%) and only four (3.5%) out of 116 survivors
developed a second malignant neoplasm after a median
follow-up of 8.5 years. Prevalences of thyroid damage,
cardiac and pulmonary late effects were also dramatically
lower than in older cohorts, reaching only 14.5%, 2.5% and
8% respectively. Basing on the excellent results of the
German (GPOH) study, a newer protocol for Hodgkin’s
lymphoma has just been released at the European level
(EuroNet-PHL-C1): basing on the results of the Positron
Emission Tomography–Computed Tomography (PET–CT)
scan after the first two OEPA courses, all patients with a
negative PET will avoid exposure to radiotherapy. Post-
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induction chemotherapy will be randomized between the
standard COPP and a less gonadotoxic COPDAC regimen.
There will be an ongoing need to systematically follow
these adolescents and young adults cured with these new
therapies. In order to get sufficient power, late-effects
studies will require to be done in the context of large,
multi-institutional and international initiatives. American
and European collaborative groups designing clinical trials
should be the leaders in establishing these long-term
cohorts, as done with the Childhood Cancer Survivor Study
[31]. With such an interdisciplinary approach, the goal of
cure while minimizing late effects is clearly achievable.
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